Comparison of Efficacy and Safety of Rosuvastatin, Atorvastatin and Pravastatin among Dyslipidemic Diabetic Patients

Table 2

Comparison of the efficacy of statins for all doses (10 mg, 20 mg, and 40 mg).

	Ator; 10 mg	Ator; 20 mg	Ator; 40 mg	Ros; 10 mg	Ros; 20 mg	Prav; 20 mg	Prav; 40 mg
% reduction LDL	−18.29^†	−19.84^†	−22.81^†	−29.03^†	−29.3^†	−20.27^†	−10.6^‡
% reduction TG	−21.05^‡	−19.95^ξ	−21.56	−25.1^ξ	−16.72	−12.63	−13.5
% reduction total cholesterol	−16.65^†	−13.95^†	−17.51^†	−22.42^†	−26.18^†	−15.91^†	−15.91^†
% increase HDL	−7.21	−5.56	−6.49^ξ	−6.64	−4.0	−5.88	−9.97
(%) patients meeting *European LDL-C goals after 2 years	60.0	44.0	50.0	56.0	58.0	48.0	32.0
(%) total cholesterol < 4 mmol/L after 2 years	40.0	32.0	19.6	38.0	44.0	30.0	24.5
(%) patients TG < 1.7 mmol/L after 2 years	64.0	56.0	39.2	58.0	54.0	50.0	55.1
(% ) patients HDL > 1 mmol/L after 2 years	70.0	74.0	68.6	66.0	65.3	68.0	74.0

∗LDL-C < 2.5 mmol/L (100 mg/dL) for patients with CVD and/or type 2 diabetes.
^†𝑃 value ≤ 0.001, ^𝜉𝑃 value ≤ 0.01, and ^‡𝑃 value ≤ 0.05.